Terumo Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Terumo ha aumentado sus beneficios a una tasa media anual de 6.3%, mientras que los beneficios de la industria de Medical Equipment han experimentado un crecimiento de 6.2% anual. Los ingresos han ido creciendo a una tasa media de 10.6% al año. La rentabilidad financiera de Terumo es de 9.1%, y sus márgenes netos son de 12.1%.

Información clave

6.3%

Tasa de crecimiento de los beneficios

6.4%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	7.8%
Tasa de crecimiento de los ingresos	10.6%
Rentabilidad financiera	9.1%
Margen neto	12.1%
Última actualización de beneficios	30 Sep 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Terumo Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 11

Returns At Terumo (TSE:4543) Appear To Be Weighed Down

Nov 08

Estimating The Fair Value Of Terumo Corporation (TSE:4543)

Sep 16

Terumo Corporation Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Aug 11

Desglose de ingresos y gastos

Cómo gana y gasta dinero Terumo. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

TSE:4543 Ingresos, gastos y beneficios (JPY Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Sep 24	986,674	119,486	365,197	0
30 Jun 24	964,805	117,716	355,378	0
31 Mar 24	921,863	106,374	343,713	0
31 Dec 23	885,167	99,042	242,094	61,583
30 Sep 23	860,767	99,096	231,405	61,583
30 Jun 23	838,121	89,476	224,786	61,583
31 Mar 23	820,209	89,325	299,861	0
31 Dec 22	797,814	87,297	219,186	51,837
30 Sep 22	761,982	79,146	205,343	51,837
30 Jun 22	728,927	83,316	191,275	51,837
31 Mar 22	703,303	88,813	178,788	51,837
31 Dec 21	688,696	90,363	177,567	49,096
30 Sep 21	675,183	95,414	171,564	49,096
30 Jun 21	654,260	91,161	167,260	49,096
31 Mar 21	613,842	77,268	160,375	49,096
31 Dec 20	607,381	76,919	158,340	50,618
30 Sep 20	604,915	71,342	160,720	50,618
30 Jun 20	607,669	76,422	160,528	50,618
31 Mar 20	628,897	85,211	165,638	50,618
31 Dec 19	626,016	89,868	170,166	47,681
30 Sep 19	621,762	90,727	167,586	47,681
30 Jun 19	608,987	84,170	165,914	47,681
31 Mar 19	599,481	79,470	164,359	47,681
31 Dec 18	594,429	84,305	153,024	41,342
30 Sep 18	588,162	92,782	156,221	41,342
30 Jun 18	591,483	93,095	157,227	41,342
31 Mar 18	587,775	91,295	157,317	41,342
31 Dec 17	576,725	85,888	193,625	33,747
30 Sep 17	553,664	66,769	182,849	33,747
30 Jun 17	528,957	60,406	174,204	33,747
31 Mar 17	514,164	54,225	167,674	33,747
31 Dec 16	503,429	39,014	165,897	33,147
30 Sep 16	510,969	44,087	166,433	33,147
30 Jun 16	520,885	46,282	168,822	33,147
31 Mar 16	525,026	50,676	170,050	33,147
31 Dec 15	522,296	48,528	171,933	29,360
30 Sep 15	515,364	43,603	169,516	29,360
30 Jun 15	503,221	44,580	164,216	29,360
31 Mar 15	489,506	38,470	159,209	29,360
31 Dec 14	485,301	30,626	131,277	30,130
30 Sep 14	474,640	36,517	179,994	0
30 Jun 14	471,214	33,534	177,652	0
31 Mar 14	467,360	34,096	123,878	30,130
31 Dec 13	451,805	59,203	134,589	27,128

Ingresos de calidad: 4543 tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (12.1%) de 4543 son superiores a los del año pasado (11.5%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de 4543 han crecido un 6.3% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de 4543 en el último año (20.6%) supera su media de 5 años (6.3% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de 4543 en el último año (20.6%) superó al de la industria Medical Equipment 5.6%.

Rentabilidad financiera

Alta ROE: La rentabilidad financiera de 4543 (9.1%) se considera baja.

Terumo Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Información clave

Actualizaciones de resultados anteriores recientes

Second quarter 2025 earnings: EPS misses analyst expectations

Terumo Corporation to Report Q2, 2025 Results on Nov 07, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat

Terumo Corporation to Report Q1, 2025 Results on Aug 08, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Terumo Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Returns At Terumo (TSE:4543) Appear To Be Weighed Down

Second quarter 2025 earnings: EPS misses analyst expectations

Terumo Corporation to Report Q2, 2025 Results on Nov 07, 2024

Upcoming dividend of JP¥13.00 per share

Estimating The Fair Value Of Terumo Corporation (TSE:4543)

Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.01% for ¥30,000 million.

Terumo Corporation Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 22%

Now 22% undervalued after recent price drop

Investors Still Waiting For A Pull Back In Terumo Corporation (TSE:4543)

Final dividend of JP¥13.00 announced

Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat

Terumo (TSE:4543) Has A Pretty Healthy Balance Sheet

Less than half of directors are independent

Return Trends At Terumo (TSE:4543) Aren't Appealing

Now 20% overvalued

Terumo Corporation to Report Q1, 2025 Results on Aug 08, 2024

Terumo Cardiovascular Announces 510(K) Clearance for the CDI Oneview™? Monitoring System

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 10% to JP¥3,255

Calculating The Fair Value Of Terumo Corporation (TSE:4543)

Investors Still Waiting For A Pull Back In Terumo Corporation (TSE:4543)

Consensus EPS estimates increase by 11%

Price target increased by 7.4% to JP¥3,136

Terumo (TSE:4543) Has Announced A Dividend Of ¥22.00

New minor risk - Dividend sustainability

Upcoming dividend of JP¥22.00 per share

Terumo Corporation to Report Fiscal Year 2024 Results on May 14, 2024

Is Terumo (TSE:4543) Using Too Much Debt?

Price target increased by 7.3% to JP¥5,548

Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Terumo Corporation, Annual General Meeting, Jun 26, 2024

Terumo Corporation to Report Q3, 2024 Results on Feb 07, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Terumo Corporation to Report Q2, 2024 Results on Nov 14, 2023

Upcoming dividend of JP¥22.00 per share at 1.1% yield

Terumo Corporation (TSE:4543) announces an Equity Buyback for 5,000,000 shares, representing 0.67% for ¥20,000 million.

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Terumo Corporation to Report Q1, 2024 Results on Aug 09, 2023

Terumo Corporation Announces Fiscal Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 28, 2023; Provides Second Quarter-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 and Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024

Full year 2023 earnings: EPS misses analyst expectations

Terumo Corporation, Annual General Meeting, Jun 27, 2023

Upcoming dividend of JP¥21.00 per share at 1.2% yield

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Less than half of directors are independent

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Terumo Corporation Announces Dividend for the Second Quarter End of Fiscal Year 2023, Commences Dividend Payments on December 5, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Terumo Corporation to Report Q3, 2023 Results on Nov 10, 2023

Terumo Corporation to Report Q2, 2023 Results on Nov 10, 2022

Upcoming dividend of JP¥18.00 per share

Mitsui DM Sugar Holdings Co.,Ltd. (TSE:2109) agreed to acquire Enteral formula business of Terumo Corporation from Terumo Corporation (TSE:4543).

NUTRI Co.,Ltd. entered into an agreement to acquire Nutritional food and related product assets of Terumo Corporation.

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Terumo Corporation Provides Dividend Guidance for the Second Quarter of Year Ending March 31, 2023

Less than half of directors are independent

Terumo Announces Change in Indication for Dexcom G6 CGM System in Japan

Full year 2022 earnings: EPS misses analyst expectations

Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.98% for ¥50,000 million.

Less than half of directors are independent

Terumo Corporation to Report Fiscal Year 2022 Results on May 12, 2022

Upcoming dividend of JP¥16.00 per share

Third quarter 2022 earnings: EPS misses analyst expectations

Terumo Corporation, Annual General Meeting, Jun 22, 2022

Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022